A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED PALBOCICLIB CLINICAL STUDIES

Who is this study for? Patients with breast cancer or head and neck cancer receiving study treatment and deriving clinical benefit in a Pfizer-sponsored palbociclib parent study
What treatments are being studied? Palbociclib
Status: Recruiting
Location: See all (22) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The purpose of this clinical trial is to provide study medicine(s) and learn about their safety. This study is seeking participants who: * Have benefited from ongoing study treatment as determined by the study doctor in a Pfizer-sponsored palbociclib Parent Study * Must agree to follow the reproductive criteria * Are willing and able to comply with all scheduled visits, treatment plans, and other study procedures * Can give signed informed consent documents Participants in this study will continue to receive treatment as they were in the parent study. The time by which participants will take part in this study is retrospective (after completed parent study). We will examine the experiences of people receiving the study medicine(s). This will help us determine if the study medicine(s) are safe. During this time, the participants will be monitored for the safety of the study medicine(s).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Any participant who is receiving study treatment and deriving clinical benefit as determined by the investigator in a Pfizer-sponsored palbociclib Parent Study

• Participants must agree to follow the reproductive criteria

• Participants who are willing and able to comply with all scheduled visits, treatment plans, and other study procedures

• Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent document and protocol

Locations
United States
California
UCSF Medical Center at Mission Bay
RECRUITING
San Francisco
Other Locations
China
Beijing Cancer Hospital
RECRUITING
Beijing
Cancer Hospital Chinese Academy of Medical Science
RECRUITING
Beijing
The First hospital of Jilin University
RECRUITING
Changchun
Sun Yat-sen Memorial Hospital of Sun Yat-sen University
RECRUITING
Guangzhou
Harbin Medical University Cancer Hospital
RECRUITING
Harbin
The First Affiliated Hospital of Anhui Medical University
RECRUITING
Hefei
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITING
Shanghai
The First Hospital of China Medical University
RECRUITING
Shenyang
Hubei Cancer Hospital
RECRUITING
Wuhan
Henan Cancer Hospital
RECRUITING
Zhengzhou
Mexico
Hospital Universitario Dr. Jose Eleuterio Gonzalez
RECRUITING
Monterrey
Republic of Korea
National Cancer Center
RECRUITING
Goyang-si
Samsung Medical Center
RECRUITING
Seoul
Seoul National University Hospital
RECRUITING
Seoul
Taiwan
National Cheng Kung University Hospital
RECRUITING
Tainan City
Mackay Memorial Hospital
RECRUITING
Taipei
Thailand
Department of Medicine, Faculty of Medicine Siriraj Hospital
RECRUITING
Bangkok
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
RECRUITING
Ratchathewi
Ukraine
Regional Municipal Non-profit Enterprise Bukovinian Clinical Oncology Center
RECRUITING
Chernivtsi
Municipal Non-profit Enterprise City Clinical Hospital #4 of Dnipro City Council
RECRUITING
Dnipro
Municipal non-profit enterprise Regional Clinical Hospital of Ivano-Frankivsk Regional Council
ACTIVE_NOT_RECRUITING
Ivano-frankivsk
Contact Information
Primary
Pfizer CT.gov Call Center
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Time Frame
Start Date: 2022-07-07
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 35
Treatments
Other: Arm 1
Cetuximab
Experimental: Arm 2
Palbociclib plus Cetuximab
Other: Arm 3
Palbociclib plus Fulvestrant
Other: Arm 4
Palbociclib plus Letrozole
Related Therapeutic Areas
Sponsors
Leads: Pfizer

This content was sourced from clinicaltrials.gov

Similar Clinical Trials